Audited Supplier
Carfilzomib
FDA, HACCP
HPLC, UV
Injection
Medicine
Powder
Chemical
Source herb
Bag/Drum
25KG/Drum, 1KG/Bag
China
Product Description
Proteasome Inhibitor Carfilzomib CAS 868540-17-4
Product Description:
| Product Name | Carfilzomib |
| CAS No. | 868540-17-4 |
| Appearance | White powder |
Carfilzomib is a cyclooxygenase inhibitor that selectively and irreversibly binds to structural and immunoproteasomes.
On July 20, 2012, the US Food and Drug Administration (FDA) approved the marketing of carfilzomib injection developed by Onyx Pharmaceuticals under the trade name Kyprolis through a priority approval process. It is used for monotherapy in multiple myeloma patients who have received at least two previous therapies, including bortezomib/Velcade and one immunomodulatory agent, and have evidence of disease progression within 60 days after completing the last treatment.
Multiple myeloma (MM) is a malignant plasma cell disease that occurs in B lymphocytes, characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, and dysfunction of monoclonal proteins and related organ functions in the blood or urine; It is the second most common hematological tumor worldwide, accounting for approximately 1% of all cancer diseases and 13% of hematological tumors. In western countries, the annual incidence rate is 5.6 cases per 100000 people.
Product Function:
Carfilzomib is the second proteasome inhibitor approved globally after bortezomib, and also the first multiple myeloma treatment drug approved by the FDA in recent years (proteasome inhibitor: the main function of the proteasome is to degrade unwanted or damaged proteins in cells, which is achieved through a chemical reaction that breaks peptide bonds. Representative drugs include bortezomib and Carfilzomib). Carfilzomib is a new generation of protease inhibitors administered intravenously, selectively targeting proteasomes in blood tumor cells, avoiding the toxic side effects caused by inhibition of constitutive proteasomes in non malignant cells.
Application:
Carfilzomib is a tetrapeptidyl epoxy backbone proteasome inhibitor that irreversibly binds to the N-terminal active site of the 20S proteasome containing threonine, and the core granules of protein hydrolysis in the 26S proteasome. Carfilzomib has anti proliferative and apoptotic activity in vitro, in both solid and hematological settings, on granulocytes. In animals, carfilzomib inhibits proteasome activity in blood and tissues, and delays tumor growth in multiple myeloma, hematological, and solid tumor models.
The US Food and Drug Administration has approved Kyprolis (cabozantinib) for the treatment of multiple myeloma patients who have previously received at least two priority therapies, including vancomycin (bortezomib) and immunomodulatory agents.
FAQ:
- What's the MOQ?
- Is there any discount?
- How can I confirm the product quality before placing orders?
- How do you treat quality complaint?
- How to contact with us ?
- How to place an order & payment ?
(2). Determine the sample,
(3).After the sample quality meets the requirements, send us the PO,
(4). We reply to PI
(5). The customer completes the payment,
(6). Receive payment for goods, export products,
(7). The customer receives the goods and completes the order.
Cooperative customers:
Our products are exported to European and American countries.
It also has a large customer base in Southeast Asia and other regions.
After-sale service:
If the quality problem is confirmed to be caused by us, we will replace the goods or refund your payment immediately!
100% responsible person, safe and reliable, integrity first.
